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Abstract
Purpose—Little research has examined cancer patients’ expectations, goals, and priorities for 
symptom improvement. Thus, we examined these outcomes in metastatic breast cancer patients to 
provide patients’ perspectives on clinically meaningful symptom improvement and priorities for 
symptom management.
Methods—Eighty women with metastatic breast cancer participated in a survey with measures of 
comorbidity, functional status, engagement in roles and activities, distress, quality of life, and the 
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modified Patient Centered Outcomes Questionnaire that focused on 10 common symptoms in 
cancer patients.
Results—On average, patients reported low to moderate severity across the 10 symptoms and 
expected symptom treatment to be successful. Patients indicated that a 49% reduction in fatigue, 
48% reduction in thinking problems, and 43% reduction in sleep problems would represent 
successful symptom treatment. Cluster analysis based on ratings of the importance of symptom 
improvement yielded three clusters of patients: (1) those who rated thinking problems, sleep 
problems, and fatigue as highly important, (2) those who rated pain as moderately important, and 
(3) those who rated all symptoms as highly important. The first patient cluster differed from other 
subgroups in severity of thinking problems and education.
Conclusions—Metastatic breast cancer patients report differing symptom treatment priorities 
and criteria for treatment success across symptoms. Considering cancer patients’ perspectives on 
clinically meaningful symptom improvement and priorities for symptom management will ensure 
that treatment is consistent with their values and goals.
Keywords
Expectation; Metastatic Breast Cancer; Patient-Centered; Priorities; Symptom; Treatment 
Outcome
Introduction
Extensive research has documented cancer patients’ symptom severity, frequency, and 
distress [1–3]; however, little is known about patients’ expectations and priorities for 
symptom improvement. Additionally, patient-defined success criteria for symptom 
improvement (i.e., goals) provides a measure of clinically meaningful improvement [7], yet 
there is a paucity of research on these criteria in cancer populations. Understanding patients’ 
expectations, priorities, and goals is crucial for patient-centered care, an approach that 
incorporates each patient’s needs, values, and preferences [4]. Evidence suggests that 
patient-centered care improves the quality of services, health outcomes, and patient 
satisfaction while reducing health care costs [5, 6].
A key component of patient-centered care is shared decision-making, defined as the process 
by which patients and providers jointly select tests, treatments, and care plans [7]. Shared 
decision-making balances evidence of risks and anticipated outcomes with patient 
expectations, goals, and priorities. This approach empowers patients to actively participate in 
their symptom management [8] and has been found to improve patients’ treatment 
adherence, satisfaction, and well-being [7].
Expectations, goals, and priorities for symptom improvement have been examined in non-
cancer populations with considerable symptom burden, such as patients with Parkinson’s 
disease, fibromyalgia, and various types of chronic pain [9–14]. These studies have found 
that many patients with chronic pain and Parkinson’s disease do not expect symptom 
treatment to meet their goals for success [10–13]. Furthermore, the expectation that 
symptom treatment will not be successful has been associated with increased anxiety and 
depressive symptoms in patients with chronic pain [13]. This research has also found 
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subgroups of chronic pain patients with different priorities for symptom improvement [10, 
12–14]. These subgroups include: patients who rate improvement in all symptoms as highly 
important, those who only rate improvement in pain as highly important, and those who rate 
improvement in all symptoms as moderately important. These subgroups of patients differ 
on clinical outcomes. Specifically, patients rating all symptoms as highly important have 
been found to experience greater fatigue, anxiety, and depressive symptoms than other 
subgroups [10, 12–14].
Findings regarding patient-centered symptom outcomes from the chronic pain literature may 
not necessarily generalize to cancer patients. Thus, the aim of our study was to provide 
initial information on cancer patients’ expectations for the treatment of 10 common physical 
and psychological symptoms, goals, and priorities for symptom improvement. We chose to 
focus on metastatic breast cancer (MBC) patients due to their prevalence [15], increasing 
longevity [16], and high symptom burden [17, 18]. Specific aims were to: 1) compare 
patients’ expected symptom level after its treatment to patients’ pre-determined threshold for 
treatment success for each of the 10 symptoms; 2) compare the degree of change considered 
a treatment success across the 10 symptoms; and 3) identify subgroups of patients based on 
their ratings of the importance of seeing improvement in each of the 10 symptoms and 
compare these subgroups with respect to usual symptom severity, demographics, and clinical 
variables.
Methods
Study Design and Participants
Following Indiana University (IU) Institutional Review Board approval, we recruited MBC 
patients from the IU Simon Cancer Center for a cross-sectional survey. Eligible patients 
were women with stage IV breast cancer who were 18+ years of age and fluent in spoken 
and written English. Eligibility was assessed via medical record review and consultation 
with oncologists. Research assistants mailed letters introducing the study and consent forms 
to patients and called them to screen for eligibility and invite participation. We excluded 
patients from study participation if they exceeded a clinical cutpoint (i.e., 3 or more errors) 
on a validated 6-item cognitive screener, as this indicates a lack of cognitive capacity to 
provide informed consent [19]. Consenting patients completed a 45- minute telephone 
assessment administered by a trained research assistant. Participants received a $40 gift card 
for study participation.
Study Variables
Clinical information—Date of the MBC diagnosis and cancer treatment history were 
collected from medical records. Additionally, patients reported whether they were diagnosed 
with or received treatment for nine common medical comorbidities within the last 3 years 
[20].
Patient-centered symptom outcomes—The Patient Centered Outcomes Questionnaire 
(PCOQ) was developed and validated to assess expectations for symptom management, 
treatment priorities, and success criteria for symptom improvement in patients with chronic 
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pain conditions [12]. For the current study, the PCOQ was modified to include 10 common 
symptoms in MBC and other cancer patients (i.e., pain, fatigue, anxiety, sadness, numbness/
tingling in hands/feet, swelling of arms or legs, nausea, hot flashes, sleep problems, 
attention/thinking/memory problems) [21–24]. The modified PCOQ consists of four 
sections, whereas the original PCOQ had five sections. We omitted the section on desired 
level of symptom severity because ideal outcomes were likely to be “none” for most patients 
[9]. In the first section, patients were asked to report their usual level of symptom severity 
over the past week on a scale from 0 (none) to 10 (worst imaginable) for each of the ten 
symptoms. In the second section, patients were asked to report for each symptom the 
severity level that they would consider a treatment success on a scale from 0 (none) to 10 
(worst imaginable). In the third section, patients were asked to report for each symptom the 
expected severity following its treatment on a scale from 0 (none) to 10 (worst imaginable). 
In the fourth section, patients were asked to rate the importance of seeing improvement in 
each symptom following its treatment on a scale from 0 (not at all important) to 10 (most 
important).
The PCOQ was initially developed for patients with chronic pain, and the original version 
showed adequate test-retest reliability over a 48-hour period (rs=0.84-0.90) and good 
convergent validity with other measures of pain, emotional distress, and disability 
(rs=0.52-0.75) [9]. In this study, items on usual symptom severity showed good convergent 
validity (rs=0.72-0.88) with the following assessments of symptom severity: PROMIS 3-
item (for pain) and 4-item measures (for anxiety, depressive symptoms, fatigue, sleep 
disturbance, and general cognitive concerns) [25], Memorial Symptom Assessment Scale 
(MSAS) items (for nausea, peripheral neuropathy, and lymphedema) [26], and a 3-item 
assessment of hot flashes [21].
Patient-reported function, distress, and quality of life—Patients’ activity 
engagement was assessed with the 6-item Patient-Reported Outcomes Information System 
(PROMIS) measure of Ability to Participate in Social Roles and Activities. For each item, 
patients were asked to rate the frequency of difficulty with social roles and activities over the 
past week on a scale from 5 (never) to 1 (always) [25]. This measure was developed with 
qualitative feedback from cancer patients and has shown good convergent validity with the 
Functional Assessment of Cancer Therapy-Functional Well-being scale (r=0.66) [27]. In this 
study, internal consistency reliability was excellent (Cronbach’s α=0.95). In addition, 
functional status was assessed with the 1-item Patient Generated Subjective Global 
Assessment (PG-SGA), a valid patient-reported version of the Eastern Cooperative 
Oncology Group [ECOG] score [28], in which patients were asked to rate their activity level 
from 0 (normal with no limitations) to 4 (pretty much bedridden, rarely out of bed). Finally, 
the single-item Distress Thermometer was used to assess distress over the past week on a 
scale from 0 (no distress) to 10 (worst distress imaginable) [29], and an item from the 
McGill Quality of Life Questionnaire was used to assess overall quality of life over the past 
2 days on a scale from 0 (very bad) to 10 (excellent) [30]. These single-item scales have 
demonstrated reliability and validity in cancer populations [28–30].
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Statistical Analyses
Data were analyzed with SPSS statistical software. Descriptive statistics were computed and 
normality was examined with skewness (<3.0) and kurtosis (<8.0) [31]. Pearson (or 
Spearman for non-normally distributed measures) correlations were used to examine 
associations between demographic, clinical, PCOQ, and additional patient-reported 
variables. Paired t-tests and Wilcoxon signed rank tests were used (as appropriate) to 
examine differences between patients’ expected symptom severity after treatment and their 
criteria for successful symptom treatment. Next, the amount of change in severity needed for 
treatment to be considered successful was computed for each of the 10 symptoms by 
subtracting patients’ success criteria from usual severity ratings. Repeated measures analysis 
of variance (ANOVA) was then conducted on the change scores to examine differences 
among the 10 symptoms. In addition, a hierarchical agglomerative cluster analysis was 
performed to examine possible subgroups of patients by ratings of the importance of seeing 
improvement in each of the 10 symptoms. Finally, one-way ANOVAs were used to examine 
potential differences between patient clusters on usual symptom severity, demographic 
information, and clinical variables. A value of p<.01 was considered statistically significant 
due to the number of comparisons.
Results
Participant Characteristics
An introductory letter and consent form were mailed to 107 MBC patients. Eighty-five 
patients (79%) completed the screening assessment, 12 (11%) could not be reached by 
phone, and 10 (9%) refused study participation. Primary reasons for patients’ refusal were 
time constraints (n=5) and illness (n=3). Two patients were found to be ineligible for study 
participation following screening (i.e., one illiterate and one non-English speaking). Of the 
83 eligible and consenting patients, 80 completed the study assessment. Participant 
characteristics are shown in Table 1.
Preliminary Analyses
Descriptive statistics for patients’ ratings on the PCOQ are presented in Table 2. PCOQ 
items were associated with a number of demographic, clinical, and additional patient-
reported variables (see Online Resource 1).
Usual Symptom Severity, Expected Severity Following Treatment, and Success Criteria
On average, fatigue, sleep problems, and thinking problems had the highest usual severity 
ratings (see Table 2), although average ratings for these symptoms were moderate (3.24-4.25 
out of 10). Paired t-tests and a Wilcoxon signed rank test for sadness (the only non-normal 
variable) showed no significant differences between ratings of expected severity after 
treatment and criteria for successful treatment (all ps>0.01); therefore, on average, 
participants expected treatment of the 10 symptoms to be successful.
Change from usual severity considered a treatment success is presented for each of the 10 
symptoms in Table 3. A repeated-measures ANOVA on these change scores showed 
significant differences between symptoms, F(6.53, 516.13)=8.48, p<0.001. Post-hoc 
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comparisons indicated greater change was needed for successful treatment of fatigue than all 
other symptoms (ps<0.01), except for sleep problems (p=0.04) and thinking problems 
(p=0.16). There was significantly greater change needed for thinking problems and sleep 
problems than swelling, nausea, and hot flashes (ps<0.01). In addition, there was 
significantly greater change needed for anxiety than swelling and nausea (ps<0.01), and 
greater change for sadness, numbness, and pain than swelling (ps<0.01).
Patient Subgroups Based on Symptom Importance
A hierarchical cluster analysis based on importance ratings for improvement in each of the 
10 symptoms yielded three clusters of patients (see Table 4). Cluster 1 consisted of 26 
patients and was labeled “Thinking, Sleep, and Fatigue-Focused,” as these symptoms were 
rated as highly important. Cluster 2 consisted of 13 patients and was labeled “Pain 
Moderately Important,” as pain was rated as moderately important and all other symptoms 
were rated low in importance. Cluster 3 consisted of 41 patients and was labeled “All Highly 
Important,” as all symptoms were rated as highly important.
In order to characterize patient clusters, they were compared on a number of characteristics. 
One-way ANOVAs were conducted to compare clusters on usual severity of the ten 
symptoms, demographic variables (i.e., age, education, income), and other clinical variables 
(i.e., duration of MBC, number of comorbid medical conditions, functional status, general 
distress, quality of life, and ability to engage in social roles and activities). Results showed 
that clusters significantly differed on the usual severity of thinking problems, F(2, 
79)=16.28, p<0.001, and years of education, F(2, 79)=5.30, p=0.007. Tukey’s honest 
significant difference tests showed that Cluster 1 reported significantly greater usual severity 
of thinking problems than Clusters 2 and 3 (ps<0.001) and more years of education than 
Cluster 2 (p=0.005). Chi-square tests showed no significant differences among the clusters 
on other demographic (i.e., race, marital status, and employment status) and clinical 
variables (i.e., cancer treatment history).
Discussion
Our study was the first to examine expectations, goals, and priorities for symptom 
improvement in a cancer patient sample. Our findings provide initial information on the 
degree of symptom reduction that advanced cancer patients consider meaningful. On 
average, MBC patients in our study reported moderate usual severity for fatigue, thinking 
problems, and sleep problems. Patients also indicated that a 49% reduction in fatigue, 48% 
reduction in thinking problems, and 43% reduction in sleep problems would represent 
successful treatment of these symptoms. Additionally, patients generally expected the 
treatment of 10 common symptoms to be successful. Although studies using the PCOQ in 
patients with chronic pain found that they did not expect symptom treatment to be successful 
[11–13], chronic pain patients have been shown to adjust their goals for successful treatment 
to be less rigorous after receiving treatment [9]. Prior experience with symptom 
management is likely in our sample as they were nearly four years post-diagnosis of MBC 
on average; therefore, patients in our sample may have expected symptom treatment to be 
successful because they had adjusted their goals.
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Whereas patients generally had positive expectations for symptom treatment, their priorities 
for symptom improvement varied. Three distinct patient subgroups based on their priorities 
for symptom improvement were identified through cluster analysis. One cluster rated 
improvement in thinking problems, sleep problems, and fatigue as highly important. Another 
cluster of patients rated pain improvement as moderately important. The third rated 
improvement in all symptoms as highly important. Consistent with their symptom 
improvement priorities, the first cluster reported greater severity of thinking problems than 
the two other clusters and a significantly higher level of education than one of the clusters. 
Prior research has found little to no correlation between subjective thinking problems and 
objective cognitive function [32]; however, subtle cognitive deficits may be particularly 
distressing for those with higher education, as they are more likely to engage in mentally 
challenging tasks [33]. Our second patient cluster focused on pain reduction; however, this 
subgroup rated pain improvement as only moderately important rather than highly important 
as found in the chronic pain literature [10, 12–14]. The moderate importance ratings for pain 
improvement in our sample may reflect the low levels of usual pain severity. Our third 
patient cluster rated improvement in all symptoms as highly important, yet did not show 
greater distress than the other patient clusters. Thus, the consistent relationship between 
symptom improvement importance and distress from the chronic pain literature [10, 12–14] 
was not replicated in our sample.
Patients most likely employed various approaches to determine their priorities for symptom 
improvement. The subgroup rating improvement in all symptoms as highly important may 
have been basing their priorities on personal experience with well or poorly managed 
symptoms, or even hypothetical rather than personal experience. Whereas poorly managed 
pain in particular is associated with greater distress in cancer patients [34], little is known 
about the influence of poor symptom management on priorities for symptom improvement. 
Future research may examine how patients’ prior experience with symptom management 
influences their ratings of symptom treatment priorities and use mixed-method designs to 
better understand cancer patients’ process of rating symptom importance.
Fatigue, sleep problems, and thinking problems required the greatest amount of 
improvement for treatment to be considered successful, had the highest usual severity 
ratings, and were rated as highly important by a subgroup. Findings regarding the 
importance of fatigue and sleep problems are consistent with prior research indicating that 
these symptoms are highly prevalent and distressing, interfere with functioning, and are 
rated by patients as highly important to monitor [3, 35–37]. Qualitative evidence suggests 
that MBC patients may prioritize treatment of symptoms which are the most bothersome and 
have the greatest functional impact [37]. Our findings regarding the importance of thinking 
problems coincide with evidence demonstrating the quality-of-life and functional impact of 
subjective and objective cognitive symptoms related to cancer and its treatment [38, 39]. 
Notably, our findings suggest that cognitive symptoms warrant clinical assessment along 
with the more commonly assessed symptoms of fatigue and sleep problems in MBC 
patients.
Limitations of the current study should be noted. First, our hierarchical cluster analysis of 
patients based on symptom importance ratings is an exploratory approach that warrants 
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replication. Additionally, the cross- sectional nature of our study precluded examining 
change in patients’ symptom severity and expectations, success criteria, and priorities for 
symptom improvement over time. Further, the MBC patients in our sample varied with 
respect to time since diagnosis and treatment history, which may have affected their 
symptom severity, expectations, and preferences. Finally, our sample primarily consisted of 
middle class Caucasian women recruited from an academic cancer center in the Midwestern 
United States. Future research may examine whether our findings generalize to diverse 
cancer patient samples and may employ longitudinal designs to identify medical and 
psychosocial predictors of patients’ expectations and priorities for symptom improvement. 
These designs would examine change in MBC patients’ symptom-related outcomes at 
different phases of medical care and disease progression.
Our findings have important implications for patient-centered care. Specifically, results 
suggest that MBC patients have heterogeneous priorities for the management of common 
symptoms. This finding highlights the need for clinicians delivering primary palliative or 
oncology care to engage in shared decision-making and tailor symptom management 
strategies to individual patient priorities. Understanding patients’ expectations, goals, and 
priorities informs the symptom management approach and discussion of possible outcomes. 
Clinicians may ask patients about their expectations and goals for symptom management 
(e.g., “What level of pain on a 0 to 10 scale do you expect after treatment? What level of 
pain on a 0 to 10 scale would you consider a successful outcome of treatment?”) and 
treatment priorities (e.g., “Thinking about your symptoms, what is most important to you 
that we improve?”).
Additionally, our findings regarding the importance of fatigue, sleep problems, and thinking 
problems indicate that these symptoms may be a focus for intervention in MBC patients. As 
these symptoms may exacerbate one another [40, 41], targeting one symptom has the 
potential to improve all three. For example, cognitive- behavioral therapy for insomnia has 
also been found to improve fatigue and thinking problems in cancer patients [42]. 
Conversely, some medical interventions may improve one symptom at the expense of 
another (e.g., stimulants for fatigue may interfere with sleep) [43]. Primary palliative care 
and oncology clinicians should consider patients’ priorities for symptom improvement when 
prescribing medications with side effects that may worsen other symptoms. Assessing 
cancer patients’ expectations, goals, and priorities for symptom improvement in conjunction 
with standard symptom assessment will ensure that treatment is consistent with their values 
and goals and ultimately promotes their quality of life.
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Table 1
Participant Characteristics (N = 80)
Characteristic
Age, mean (SDa) 55.50 (11.26)
Years of education, mean (SD) 15.03 (2.42)
Years since diagnosis of MBCb (SD)   3.93 (3.64)
Race/ethnicity, no. (%)
 Non-Hispanic White      73 (91.3)
 Other ethnicityc        7 (8.8)
Married/partnered, no. (%)      53 (66.3)
Employed, no. (%)      24 (30.0)
Household Income, no. (%)
 $0-$30,999      17 (21.8)
 $31,000-$50,999      18 (23.1)
 $51,000-$99,999      26 (33.3)
 $100,000+      17 (21.8)
Cancer treatment history, no. (%)
 Lumpectomy      17 (21.3)
 Mastectomy      53 (66.3)
 Radiation      52 (65.0)
 Endocrine therapy      68 (85.0)
 Chemotherapy      69 (86.3)
 Targeted therapyd      36 (45.0)
Medical comorbidities, mean (SD)   0.95 (0.95)
aSD = standard deviation.
b
MBC = metastatic breast cancer.
cAfrican American/Black, Hispanic, and other.
d
Targeted therapies were trastuzumab and bevacizumab.
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Table 3
Amount of Change Necessary for Treatment to be Considered Successful
Change for Treatment Success Meana (%)b SDc
Fatigue 2.08 (48.94) 2.64
Thinking problems 1.69 (48.42) 3.02
Sleep problems 1.40 (43.21) 2.91
Anxiety 1.10 (44.35) 2.28
Sadness 0.96 (41.56) 2.07
Numbness 0.94 (37.45) 2.72
Pain 0.86 (30.39) 2.49
Hot flashes 0.49 (23.00) 2.90
Nausea 0.34 (25.19) 2.08
Swelling
−0.09 (−9.00)d 1.83
a
Mean calculated by subtracting symptom levels defined by patients as a treatment success from usual symptom levels.
b
Percentage = (mean reduction in usual symptom severity/mean of usual symptom severity)*100.
cSD = standard deviation.
d
For swelling, mean ratings of severity after successful treatment were greater than mean ratings of usual severity.
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